The short version of freeze-thaw cycle fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-02-10. Anything still debated is marked as such rather than presented as settled.
Melanotan-2 is frequently confused with afamelanotide, a linear analogue authorised in the European Union for erythropoietic protoporphyria. The two compounds differ in chain length, ring structure and receptor selectivity, so findings for one cannot be transferred directly to the other. Published controlled human data on melanotan-2 remain sparse, and much of what circulates online derives from small studies or unpublished reports. Questions about effect size, dose-response behaviour and long-term safety therefore remain unresolved.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone. Its sequence incorporates a lactam bridge that constrains the peptide into a ring, which increases resistance to enzymatic breakdown relative to the natural hormone. Researchers at the University of Arizona synthesised the compound in the late 1980s and early 1990s while studying pigmentation pathways. It has never received marketing approval from any national medicines regulator. In the scientific literature it is usually described as a laboratory research reagent rather than a therapeutic product.
The peptide acts as a non-selective agonist at melanocortin receptors, showing affinity for MC1R, MC3R, MC4R and MC5R. Activation of MC1R on melanocytes drives the conversion of tyrosine into melanin and shifts production toward the darker eumelanin form. MC4R signalling in the central nervous system is linked to appetite and energy balance, which helps explain why reduced food intake appeared in early human studies. Effects on MC4R and on vascular tone also account for the erectile responses recorded as unexpected findings in those same trials.
Published research on the compound remains limited. Much of the human data comes from small, early-stage studies rather than large controlled trials, and several questions about effects and variability between individuals remain open. Investigators have examined receptor activity, pigment pathways, and related physiological responses in laboratory and animal models. Findings from those models do not automatically translate to human outcomes. Reviews frequently note the scarcity of rigorous clinical evidence and call for better-characterized study material.
Because the substance circulates mainly through informal markets, verification is a recurring theme in technical discussion. Independent analyses have found that labeled content and actual content can diverge, and that purity varies between samples. Analytical laboratories use reversed-phase chromatography to separate components and mass spectrometry to confirm identity. Isotope-labeled internal standards improve quantification in complex matrices. Such methods describe what a sample contains but say nothing about its sterility, lawful status, or suitability for any use. Open questions remain about how consistently testing is applied across the supply chain.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic cyclic heptapeptide | Alpha-MSH analogue with a lactam ring |
| Molecular formula | C50H69N15O9 | Commonly cited value for the neutral peptide |
| Molecular weight | 1024.18 g/mol | Calculated for the free molecule |
| Appearance | White to off-white powder | Typically supplied as a lyophilised solid |
| Solubility | Soluble in water, DMSO and ethanol | Dissolution in pure water is often slow |
Outside regulated medicine, melanotan II circulates through online vendors as a research chemical, often marketed for tanning. Products sold this way vary widely in purity, concentration, and labeling accuracy, and independent testing has documented discrepancies. Published reports describe both pigment effects and adverse reactions, including nausea, flushing, and darkening of existing moles. Long-term safety data are sparse, and no large controlled trial has established a risk profile. Questions about cumulative effects on melanocytes remain unresolved in the literature.
Melanotan II is a synthetic peptide analog modeled on alpha-melanocyte-stimulating hormone, a naturally occurring signaling peptide involved in pigmentation. Its structure is a cyclic heptapeptide containing two non-natural substitutions, norleucine at position four and D-phenylalanine at position seven. These modifications resist enzymatic breakdown and extend the molecule's activity relative to the native hormone. The compound binds melanocortin receptors and is studied mainly as a pharmacological tool rather than a therapeutic product. It has never received approval as a medicine in any major jurisdiction.
Routine characterisation relies on reversed-phase high-performance liquid chromatography with ultraviolet detection near 214 nanometres, using a C18 column and a water-acetonitrile gradient containing trifluoroacetic acid. Electrospray ionisation mass spectrometry confirms the expected molecular mass and can reveal truncated or oxidised by-products that co-elute poorly. Sequence and stereochemistry require additional work, such as peptide mapping or amino acid analysis, because a chromatographic purity figure alone does not distinguish a diastereomer from the target peptide. Independent testing of research-grade material frequently shows measured content below the stated label, so a certificate of analysis is best read together with the method that produced it.
Melanotan-2 is handled in the laboratory as a lyophilised powder that dissolves readily in water, dimethyl sulfoxide and dimethylformamide, with limited solubility in ethanol. Stock solutions prepared in an organic solvent often precipitate when diluted into aqueous buffer, so gradual dilution with mixing is standard practice. The peptide carries a tryptophan residue and a histidine residue, both sensitive to oxidation and to alkaline conditions. Working solutions are therefore kept near neutral to slightly acidic pH, protected from light, and consumed within the same working session whenever that is practical.
=== Troll Center case === In January 2016, the El Diario de Hoy and La Prensa Gráfica newspapers reported that the Búnker digital-programming company had created mirror sites of the newspapers in June 2015 and posted false information in an attempt to damage their reputations; the newspapers described the incident as a cyberattack. In a subsequent investigation by the office of the attorney general (FGR), Bukele allegedly instructed a Twitter user to create the mirror sites. Bukele denied involvement in the creation of the mirror sites. The incident became known as the "Troll Center" case. Five people were charged in relation to the case, but the charges were dropped in December 2017. On 4 July 2017, Bukele sued La Prensa Gráfica for $6 million, alleging that the newspaper had defamed and slandered him in its reporting of the cyberattacks by "falsely" ("falsamente") connecting him to the Troll Center case and "damag[ing] [Bukele's] image" ("dañó la imagen del señor alcalde"). Later that month, a court dismissed Bukele's lawsuit and three other courts rejected his appeals. In December 2018, the FGR stated that it had reviewed information supposedly linking Bukele's cell phone to the cyberattacks.
=== Adrian Shephard === Adrian Shephard is the protagonist of Half-Life: Opposing Force. He is a 22-year old corporal in the United States Marine Corps (USMC) stationed at the fictional Santego Military Base in Arizona who is mysteriously transferred to the Hazardous Environment Combat Unit (HECU), a special USMC unit. Three months after his transfer, he is sent to the Black Mesa Research Facility (BMRF) to defeat the Xenian invasion and summarily execute all BMRF personnel. However, the Bell Boeing V-22 Osprey transporting him is hit by a Xenian energy blast and crashes; he is rescued by a group of Black Mesa scientists, and due to never making it to his designated landing zone, Shephard remains unaware of the secret orders to kill all BMRF employees. Making his way through the facility while being observed by the G-Man, he eventually comes across a thermonuclear weapon brought in by the Central Intelligence Agency and deactivates it, but the G-Man later reactivates it, leading to the eventual destruction of Black Mesa. In the end, the G-Man reveals that he has successfully argued for Shephard's life, detaining him in some unknown void. The G-Man expresses a degree of respect for Shephard, offering praise for his ability to "adapt and survive against all odds" which "rather reminds [the G-Man] of [himself]". Shephard is briefly mentioned in Half-Life: Blue Shift, where a HECU marine grumbles about taking over some of Shephard's squad's duties.
== Drawbacks == Acromegaly patients, who suffer from natural growth hormone levels of up to 100 times higher than normal, have lower stamina towards physical activity than people with regular levels. When the patients are treated and their growth hormone levels decrease, their stamina improves. This knowledge is part of the evidence behind the new belief that athletes who use supplemental HGH to raise their levels far above average could actually decrease their exercise tolerance, and thus hurt their athletic performance. Further backing was provided in a study done by the Danish Institute of Sports Medicine. They found cyclists of good health and endurance "were unable to complete accustomed cycling tasks after administration of exogenous hGH" and concluded that HGH can inhibit recuperation from exercise. Participants have also been found to have lower stamina after HGH treatment along with higher rates of fatigue. Although adverse side effects can result from excessive doses, typical GH therapy has few side effects and those have likely been overstated due to the excessive amounts administered in earlier studies.
== Structure == The party president is the top position of SWAPO; in 2012 this was held by Namibia's former president Pohamba. The vice-president was Namibia's former president Hage Geingob, who was elected to that position in 2007 and reconfirmed at the SWAPO congress in December 2012, until his death on 4 February 2024. The third highest position in SWAPO is the secretary-general, a position held in December 2012 by Nangolo Mbumba. Number four is the deputy secretary-general, Omaheke governor Laura McLeod-Katjirua. Like many socialist and communist parties, SWAPO is governed by a politburo and a central committee. The party leadership is advised by a youth league, a women's council, and an elders' council.
Sources: en.wikipedia.org
Immunogen — an antigen that is capable of inducing an immune response, i.e., it is immunogenic. Antigen is often used interchangeably with this term, but this is not, strictly speaking, correct. All immunogens are antigens, but not all antigens are immunogens. The antigen within a vaccine is often referred to as an immunogen, even if, strictly speaking, its purified form cannot induce immune responses (requiring adjuvants to do so). For simplicity, many sources use the term "antigen" in place of "immunogen," but these terms should not be regarded as interchangeable. Allergen – A substance capable of causing an allergic reaction in sensitized individuals. The reaction may result after exposure via ingestion, inhalation, injection, or contact with skin. Tolerogen – A substance that invokes immune tolerance. This property is related to its molecular properties and circumstances such as route of administration. Superantigen – A class of antigens that cause non-specific activation of T-cells, resulting in polyclonal T-cell activation and massive cytokine release. Immunoglobulin-binding protein – Proteins such as protein A, protein G, and protein L that are capable of binding to antibodies at positions outside of the antigen-binding site (paratope). These are sometimes known as B cell superantigens. Epitope – The specific part of an antigen that is bound by an antibody (or T cell receptor), its antigenic determinant.Antigenic molecules, normally "large" biological polymers, usually present surface features that can act as points of interaction for specific antibodies.
Medical schools began to be set up in the United States towards the end of the 18th century. Classes in anatomy needed a continual stream of cadavers for dissection, and these were difficult to obtain. Philadelphia, Baltimore, and New York were all renowned for body snatching activity as criminals raided graveyards at night, removing newly buried corpses from their coffins. A similar problem existed in Britain where demand for bodies became so great that grave-raiding and even anatomy murder were practised to obtain cadavers. Some graveyards were, in consequence, protected with watchtowers. The practice was halted in Britain by the Anatomy Act of 1832, while in the United States, similar legislation was enacted after the physician William S. Forbes of Jefferson Medical College was found guilty in 1882 of "complicity with resurrectionists in the despoliation of graves in Lebanon Cemetery".The teaching of anatomy in Britain was transformed by Sir John Struthers, Regius Professor of Anatomy at the University of Aberdeen from 1863 to 1889. He was responsible for setting up the system of three years of "pre-clinical" academic teaching in the sciences underlying medicine, including especially anatomy. This system lasted until the reform of medical training in 1993 and 2003. As well as teaching, he collected many vertebrate skeletons for his museum of comparative anatomy, published over 70 research papers, and became famous for his public dissection of the Tay Whale. From 1822 the Royal College of Surgeons regulated the teaching of anatomy in medical schools.
Depression, substance use disorders, relationship problems, premenstrual syndrome, and autism were among several psychiatric disorders MDMA assisted therapy was reported to treat. According to psychiatrist George Greer, therapists who used MDMA in their practice were impressed by the results. Anecdotally, MDMA was said to greatly accelerate therapy. According to David Nutt, MDMA was widely used in the western US in couples counseling, and was called empathy. Only later was the term ecstasy used for it, coinciding with rising opposition to its use.
=== Development === Development of the film was announced on 20 December 2008, although writer Alex Garland had begun working on the script in 2006. British studio DNA Films produced the film, and partnered with sales agency IM Global to sell the worldwide distribution rights. By May 2010, this partnership saw IM Global and its owner Reliance Big Pictures agree to co-finance the 3-D project with a $45 million production budget, and a schedule to begin filming in Johannesburg, South Africa in late 2010. Pete Travis was named as the film's director and Garland, Andrew Macdonald and Allon Reich would produce it. Duncan Jones had previously been offered the role of director. In a 2010 interview, Jones said that his vision for the film was unconventional—describing it as weird, dark, and funny—and it did not mesh well with Garland's script. In September 2010, it was reported that the film would be titled Dredd. Pre-production commenced on 23 August 2010 at Cape Town Film Studios in Cape Town, South Africa. During the 2010 San Diego Comic-Con in July, Urban confirmed that he had been offered the role of Judge Dredd, and on 18 August 2010, it was reported that Urban had the role. In September 2010, it was announced that Thirlby would play Dredd's telepathic rookie Cassandra Anderson. In the same month during the Toronto International Film Festival, the film attracted $30 million in worldwide pre-sales to distributors in 90% of theatrical markets. The sales included a $7 million deal with British distributor Entertainment Film Distributors.
From May 2004 to April 2012, Surya Mohapatra served as the company's President and CEO. In 2007 Quest acquired diagnostic testing equipment company AmeriPath. In response to Mohapatra's resignation after eight years with Quest, former Philips Healthcare CEO Stephen Rusckowski was appointed. Under Rusckowski, Quest Diagnostics teamed up with central New England's largest health care system, UMass Memorial Health Care, to purchase its clinical outreach laboratory.
Sources: en.wikipedia.org
=== Native chemical ligation === Native chemical ligation (NCL) is a convergent synthetic strategy based on the linear coupling of glycopeptide fragments. This technique makes use of the chemoselective reaction between a N-terminal cysteine residue on one peptide fragment with a thio-ester on the C-terminus of the other peptide fragment as illustrated below.
A trackway consisting of four footprints discovered near Marmarth, North Dakota in 2025 and described in 2026 have been attributed to an adult Tyrannosaurus based on the shape and size of the tracks, which measure 1 m (3.3 ft). The set of tracks suggests a stride length of 4 m (13 ft) for the animal that made them, with speed estimates of 1.5–2 meters per second (3.4-4.5 mph). The fluvial environment of the upper Hell Creek Formation, from which the footprints were unearthed may explain the significant scarcity of trackways and the uncommon nature of theropod footprints in the formation in general. Three of the footprints are expected to be recovered in autumn of 2026 to be displayed at the Denver Museum of Nature and Science.
=== Retinoic acids and photodamage === UV radiation decreases the expression of both retinoic acid receptors and retinoid x receptors in human skin, thereby resulting in a complete loss of the induction of RA-responsive genes. It also leads to an increase in activity of the AP-1 pathway, increasing MMP activity and thus resulting in a functional deficiency of vitamin A in the skin.
This test can be used to measure the aggregate modulus of cartilage, which is typically in the range of 0.5 to 0.9 MPa for articular cartilage, and the Young's Modulus, which is typically 0.45 to 0.80 MPa. The aggregate modulus is "a measure of the stiffness of the tissue at equilibrium when all fluid flow has ceased", and Young's modulus is a measure of how much a material strains (changes length) under a given stress. The confined compression test can also be used to measure permeability, which is defined as the resistance to fluid flow through a material. Higher permeability allows for fluid to flow out of a material's matrix more rapidly, while lower permeability leads to an initial rapid fluid flow and a slow decrease to equilibrium. Typically, the permeability of articular cartilage is in the range of 10^-15 to 10^-16 m^4/Ns. However, permeability is sensitive to loading conditions and testing location. For example, permeability varies throughout articular cartilage and tends to be highest near the joint surface and lowest near the bone (or "deep zone"). Permeability also decreases under increased loading of the tissue. Indentation testing is an additional type of test commonly used to characterize cartilage. Indentation testing involves using an indentor (usually <0.8 mm) to measure the displacement of the tissue under constant load. Similar to confined compression testing, it may take hours to reach equilibrium displacement. This method of testing can be used to measure the aggregate modulus, Poisson's ratio, and permeability of the tissue.
Latent period: During the haemostatic and inflammatory phase of the wound healing process, vasodilation and permeabilisation allow leukocyte extravasation and phagocytic debridement and decontamination of the wound area. Tissue swelling aids later angiogenesis by expanding and loosening the existing collagenous extracellular matrix. Endothelial activation: As the wound macrophages switch from inflammatory to healing mode, they begin to secrete endothelial chemotactic and growth factors to attract adjacent endothelial cells. Activated endothelial cells respond by retracting and reducing cell junctions, loosening themselves from their embedded endothelium. Characteristically the activated endothelial cells show enlarged nucleoli. Degradation of endothelial basement membrane: The wound macrophages, mast cells and the endothelial cells themselves secrete proteases to break down existing vascular basal lamina. Vascular sprouting: With the breakdown of endothelial basement membrane, detached endothelial cells from pre-existing capillaries and post-capillary venules can divide and migrate chemotactically towards the wound, laying down new vessels in the process. Vascular sprouting can be aided by ambient hypoxia and acidosis in the wound environment, as hypoxia stimulates the endothelial transcription factor, hypoxia inducible factor (HIF) to transactivate angiogenic genes such as VEGF and GLUT1. Sprouted vessels can self-organise into luminal morphologies, and fusion of blind channels give rise to new capillary networks.
Sources: en.wikipedia.org
It is a synthetic cyclic heptapeptide modelled on alpha-melanocyte-stimulating hormone. A lactam bridge links two side chains, forming a ring that stabilises the molecule against proteolysis. It belongs to the broader melanocortin peptide family.
No national medicines agency has approved melanotan-2 for clinical use. Afamelanotide, a related but distinct peptide, holds a marketing authorisation in the European Union for a rare photosensitivity disorder. Melanotan-2 itself is handled as a laboratory chemical.
Its broad activity across melanocortin receptors makes it a tool for probing pigmentation, appetite and vascular signalling. Early trials recorded skin darkening and other effects that were not the original focus of the work. Those observations generated hypotheses that later studies have examined.
Only a small number of early-stage human studies have been reported, and most were limited in size and duration. No large late-stage program has established a general efficacy or safety profile. The evidence base is therefore thin compared with approved medicines.